



JEA BizDev Consulting Advises NovaRock Biotherapeutics on Partnership with Bionyra Pharma

CLIENT SHOWCASE

June 22, 2026

[JEA BizDev Consulting, LLC](#) advised NovaRock Biotherapeutics, Inc. on an exclusive license agreement with Bionyra Pharma for the development and commercialization of NBL-023, a novel monoclonal antibody targeting Interleukin-25 (IL-25). Under the terms of the agreement, Bionyra receives worldwide rights to NBL-023 outside Greater China.

JEA BizDev Consulting served as lead business development and transaction advisor to NovaRock Biotherapeutics in connection with this strategic partnership. Financial terms of the license agreement were not disclosed.

The JEA BizDev Consulting team was led by [John Adamou](#), President and Managing Director.

For additional details, please refer to the accompanying [news release](#).